Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kisspeptin to Quantify GnRH Neuronal Function in Post-COVID-19 Syndrome
NCT07224490Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- May 2030
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kisspeptin 112-121 in post-COVID-19 condition (PCC). Primary endpoint: Difference in mean luteinizing hormone amplitude. Started Mar 2026; status: recruiting.
02
Drugs
kisspeptin 112-121
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT07224490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224490.